Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Oct 2010

Price Katharine A, Azzoli Christopher G, Krug Lee M, Pietanza Maria C, Rizvi Naiyer A, Pao William, Kris Mark G, Riely Gregory J, Heelan Robert T, Arcila Maria E, Miller Vincent A

Abstract excerpt

INTRODUCTION: Concurrent signal transduction inhibition with the epidermal growth factor receptor (EGFR) inhibitor gefitinib and the mammalian target-of-rapamycin inhibitor everolimus has been hypothesized to result in enhanced antitumor activity in patients with non-small cell lung cancer (NSCLC). This phase II trial assessed the efficacy of the combination of gefitinib and everolimus in patients with advanced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase I as Topic
Share to Everolimus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gefitinib

Share to Quinazolines

Share to ras Proteins

Share to Salvage Therapy

Share to Sirolimus

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 20871262
DOI: 10.1097/JTO.0b013e3181ec1531
PMCID: PMC4020424

Genes

EGFR
KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer.PMID 20871262Read ↗

A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer.Semantic proximity Read ↗

A Phase I Trial of Temsirolimus and Pemetrexed in Patients with Advanced Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors.Semantic proximity Read ↗

Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.Semantic proximity Read ↗

A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations.Semantic proximity Read ↗

Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy.Semantic proximity Read ↗

A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer.Semantic proximity Read ↗

Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer.Semantic proximity Read ↗

Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.Semantic proximity Read ↗

Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.Semantic proximity Read ↗

mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.